Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03960866 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma
A Phase 2 study, sponsored by Ocuphire Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT03960866: Completed Phase 2 study, sponsored by Ocuphire Pharma.
NCT03960866 is a Phase 2 study that has completed, run by Ocuphire Pharma. The registered enrollment target is 39 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03960866, a Phase 2 study, has completed, sponsored by Ocuphire Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
The objectives of this study are: * To evaluate the efficacy of Phentolamine Mesylate to lower intra-ocular pressure (IOP) in the treatment of Open-Angle Glaucoma (OAG) and Ocular Hypertension (OHT). * To evaluate the ocular and systemic safety of Phentolamine Mesylate compared to its vehicle. * To evaluate additional efficacy of Phentolamine Mesylate to improve visual performance.
Primary Outcome
change from Baseline in mean diurnal IOP in the study eye
Interventions
- OTHER Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
- DRUG Phentolamine Mesylate Ophthalmic Solution 1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2019-05-28 |
| Est. Completion | 2019-09-11 |
| Phase | Phase 2 |
What the finished NCT03960866 record still lists
NCT03960866 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower).
The record links to 0 conditions, and to 2 interventions - of which Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo) is the first listed.
NCT03960866 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03960866 about?
NCT03960866 is a clinical study titled "Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma". The objectives of this study are: * To evaluate the efficacy of Phentolamine Mesylate to lower intra-ocular pressure (IOP) in the treatment of Open-Angle Glaucoma (OAG) and Ocular Hypertension (OHT). * To evaluate the ocular and systemic safety of Phentolamine Mesylate compared to its vehicle. * To...
What is the current status of trial NCT03960866?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2019-05-28. Estimated completion is 2019-09-11.
What interventions are being tested in trial NCT03960866?
The interventions under investigation include: Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo) (OTHER), Phentolamine Mesylate Ophthalmic Solution 1% (DRUG).
Who is sponsoring clinical trial NCT03960866?
This trial is sponsored by Ocuphire Pharma, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03960866's enrollment target sits among peer trials
39 1459th of 2000 higher than 534 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI